Actuate Therapeutics Inc (ACTU)
7.09
0.27 (3.96%)
At close: Apr 08, 2025, 2:06 PM
Company Description
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers.
The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma.
It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015.
The company was incorporated in 2015 and is based in Fort Worth, Texas.
Actuate Therapeutics Inc
| Country | United States |
| IPO Date | Aug 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Dr. Andrew P. Mazar Ph.D. |
Contact Details
Address: 1751 River Run Fort Worth, Texas United States | |
| Website | https://actuatetherapeutics.com |
Stock Details
| Ticker Symbol | ACTU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001652935 |
| CUSIP Number | 005083100 |
| ISIN Number | US0050831009 |
| Employer ID | 47-3044785 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew P. Mazar Ph.D. | Co-Founder & Chief Operating Officer |
| Paul J. Lytle CPA | Chief Financial Officer |
| Dr. Alan Kozikowski Ph.D. | Scientific Founder and Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 02, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Mar 28, 2025 | S-1 | Filing |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 10-K | Annual Report |
| Feb 07, 2025 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |